South Dakota Investment Council Acquires 191,663 Shares of Boston Scientific Corporation $BSX

South Dakota Investment Council increased its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 71.5% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 459,826 shares of the medical equipment provider’s stock after purchasing an additional 191,663 shares during the period. South Dakota Investment Council’s holdings in Boston Scientific were worth $20,071,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Kelleher Financial Advisors bought a new stake in Boston Scientific during the 2nd quarter valued at approximately $25,000. Clal Insurance Enterprises Holdings Ltd bought a new position in Boston Scientific in the 1st quarter worth approximately $28,000. Nvwm LLC increased its position in Boston Scientific by 526.2% in the 3rd quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 542 shares during the period. Rakuten Securities Inc. bought a new position in Boston Scientific in the 2nd quarter worth approximately $30,000. Finally, Kings Path Partners LLC bought a new position in Boston Scientific in the 3rd quarter worth approximately $31,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of research analyst reports. Raymond James Financial reiterated an “outperform” rating and set a $57.00 price target (down from $78.00) on shares of Boston Scientific in a report on Thursday, July 30th. Needham & Company LLC dropped their target price on shares of Boston Scientific from $57.00 to $48.00 and set a “buy” rating on the stock in a research report on Wednesday, October 28th. Wells Fargo & Company cut their target price on shares of Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating for the company in a research note on Thursday, October 29th. Sanford C. Bernstein reduced their price target on shares of Boston Scientific from $54.00 to $49.00 and set an “outperform” rating for the company in a report on Thursday, October 29th. Finally, Citigroup decreased their price target on shares of Boston Scientific from $48.00 to $44.00 and set a “neutral” rating on the stock in a research report on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $61.43.

Check Out Our Latest Analysis on Boston Scientific

Boston Scientific Trading Down 1.5%

Boston Scientific stock opened at $43.06 on Wednesday. The business has a 50 day moving average price of $43.87 and a two-hundred day moving average price of $54.00. The company has a quick ratio of 0.81, a current ratio of 1.36 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 12 month low of $39.57 and a 12 month high of $101.91. The stock has a market cap of $62.41 billion, a price-to-earnings ratio of 18.24, a price-to-earnings-growth ratio of 1.29 and a beta of 0.60.

Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter last year, the firm earned $0.75 EPS. Boston Scientific’s revenue for the quarter was up 1.4% compared to the same quarter last year. As a group, equities analysts forecast that Boston Scientific Corporation will post 3.17 EPS for the current year.

Boston Scientific Profile

(Free Report)

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Further Reading

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.